What is isoalbumin, how is it prepared, and what is its evidence‑based role in sepsis?

What is Isoalbumin, How to Prepare It, and Its Evidence-Based Role in Sepsis

The term "isoalbumin" does not appear in standard medical literature or clinical guidelines; you likely mean "albumin" (human albumin solution), which is available as 4–5% or 20–25% formulations and is used as a colloid fluid in sepsis resuscitation when patients require substantial amounts of crystalloids, though its mortality benefit remains unproven.

---

What is Albumin (Human Albumin Solution)

• Albumin is a plasma-derived protein product available in two main concentrations: 4–5% (iso-oncotic) and 20–25% (hyperoncotic). 1
• It functions as a volume expander by increasing intravascular oncotic pressure and may have anti-inflammatory and endothelial-stabilizing properties in sepsis. 2
• Albumin is not synthesized or "prepared" at the bedside; it is a commercially manufactured blood product derived from pooled human plasma through fractionation and pasteurization. 1

---

How Albumin is Administered in Sepsis

Dosing and Timing

• The typical dose is 20% albumin at 100–200 mL (20–40 g) per bolus, repeated as needed, or 4–5% albumin at larger volumes (e.g., 500 mL). 3
• In the ALBIOS trial, patients received a median of 70 g daily over 3 days (median total 175 g) to maintain serum albumin ≥30 g/L until ICU discharge or 28 days. 3, 4
• Albumin is added after initial crystalloid resuscitation (at least 30 mL/kg within 3 hours) when patients require substantial ongoing volume support. 1, 5

Administration Technique

• Infuse albumin intravenously over 30–60 minutes for 20–25% solutions; 4–5% solutions can be given more rapidly. 1
• Monitor hemodynamic response continuously using dynamic measures (pulse-pressure variation, stroke-volume variation) or static clinical signs (MAP, heart rate, urine output, lactate clearance). 5
• Stop albumin if signs of fluid overload develop (pulmonary crackles, worsening respiratory distress, jugular venous distension). 6

---

Evidence-Based Role of Albumin in Sepsis

Guideline Recommendations

The Surviving Sepsis Campaign (2021) and International Collaboration for Transfusion Medicine Guidelines (2024) provide weak recommendations for albumin use:

• Albumin may be added to crystalloids when patients require substantial amounts of crystalloids (weak recommendation, low-quality evidence). 1
• Crystalloids remain the first-line fluid for initial resuscitation and subsequent volume replacement (strong recommendation, moderate-quality evidence). 1
• The lack of proven mortality benefit and higher cost of albumin contributed to the strong recommendation for crystalloids as first-line therapy. 1

High-Quality Evidence on Mortality

The most recent and highest-quality evidence shows no mortality benefit from albumin in sepsis:

• The 2024 International Collaboration guideline systematic review found no difference in mortality, need for kidney replacement therapy, or other critical outcomes when albumin was compared to crystalloid across a wide range of critically ill patient subgroups. 1
• The 2014 ALBIOS trial (N=1,818), the largest RCT to date, found no difference in 28-day mortality (31.8% albumin vs. 32.0% crystalloid; RR 1.00,95% CI 0.87–1.14) or 90-day mortality (41.1% vs. 43.6%; RR 0.94,95% CI 0.85–1.05). 3
• A 2014 systematic review and trial sequential analysis (16 trials, 4,190 patients) found no mortality benefit (RR 0.94,95% CI 0.87–1.01), with the cumulative z-score entering the futility area, suggesting further trials are unlikely to change this conclusion. 4

Emerging Safety Concerns

Recent observational data suggest potential harm from early albumin use:

• A 2025 target trial emulation (N=27,088 matched pairs) found that early albumin administration was associated with a significantly higher risk of sepsis-associated acute kidney injury (relative difference 3.47%, 95% CI 1.76–5.23) without any short-term survival benefit (relative difference 0.05%, 95% CI -2.30 to 2.45). 7
• This finding requires cautious interpretation given its observational design, but it underscores the need for rigorous risk-benefit assessment when incorporating albumin into sepsis protocols. 7

Potential Subgroup Benefit

Some evidence suggests possible benefit in specific sepsis subgroups, though this remains controversial:

• A 2024 meta-analysis found that 20% albumin and high daily doses (>70 g/day) might benefit patients with septic shock (RR 0.89, P=0.03 and RR 0.90, P=0.03, respectively), but the overall recommendation remains against routine use. 8
• The 2014 ALBIOS trial showed higher mean arterial pressure and lower net fluid balance in the albumin group, but this did not translate into improved survival or organ function. 3

---

Clinical Algorithm for Albumin Use in Sepsis

Step 1: Initial Resuscitation (First 3 Hours)

• Give at least 30 mL/kg of crystalloid (balanced crystalloids preferred over normal saline). 1, 5, 9
• Do not use albumin as first-line fluid; crystalloids are strongly recommended. 1

Step 2: Assess Response and Need for Additional Volume

• Continue crystalloid boluses while hemodynamic parameters improve (MAP ≥65 mmHg, improving lactate, urine output, mental status). 5, 9
• Start norepinephrine if MAP remains <65 mmHg despite adequate fluid resuscitation. 1, 5

Step 3: Consider Albumin as Rescue Fluid (Weak Recommendation)

• Add albumin only if:

  • Patient has received several liters of crystalloid (typically ≥3–4 L) and still requires ongoing volume support. 1
  • Serum albumin is low (<30 g/L) and prolonged shock is present. 3
  • Patient is developing hyperchloremic acidosis from large-volume saline resuscitation. 5

• Do not add albumin if:

  • Active pulmonary edema or decompensated heart failure is present. 5, 9
  • Patient is responding adequately to crystalloids alone. 1
  • Chronic kidney disease with limited fluid excretion capacity is present (use cautiously with close monitoring). 6

Step 4: Dosing and Monitoring

• Give 20% albumin 100–200 mL (20–40 g) per bolus, targeting serum albumin ≥30 g/L. 3
• Reassess after each bolus for hemodynamic improvement and signs of fluid overload. 5, 6
• Stop albumin if no improvement occurs or fluid overload develops. 5, 9, 6

---

Critical Pitfalls and Caveats

Common Mistakes to Avoid

• Do not use albumin as first-line fluid in place of crystalloids; this contradicts strong guideline recommendations. 1
• Do not use hydroxyethyl starch solutions; they increase mortality and acute kidney injury in sepsis (strong recommendation, high-quality evidence). 1, 5
• Do not rely on central venous pressure (CVP) alone to guide fluid therapy; it has poor predictive value for fluid responsiveness. 9
• Do not give large albumin boluses in children with severe malaria or febrile illness; the FEAST trial showed excess mortality with albumin boluses in this population (RR 1.45,95% CI 1.10–1.92). 1

Special Populations Requiring Caution

• Patients with chronic kidney disease may develop fluid overload more readily; use smaller boluses (250–500 mL) and reassess frequently. 6
• Patients with reduced ejection-fraction heart failure should receive the initial 30 mL/kg crystalloid bolus but require close monitoring for cardiogenic pulmonary edema; consider early inotropic support (dobutamine) if low cardiac output persists. 5, 9
• Pediatric patients with severe malaria or profound anemia should not receive large-volume albumin boluses; consider blood transfusion instead. 1, 9

Weighing Cost and Benefit

• Albumin is significantly more expensive than crystalloids without proven mortality benefit, which influenced the Surviving Sepsis Campaign's strong recommendation for crystalloids as first-line therapy. 1
• The 2025 observational study suggesting increased AKI risk with early albumin use highlights the need for careful patient selection and further clinical validation. 7

---

Summary of Strength of Evidence

• High-quality evidence (GRADE moderate to high) supports crystalloids as first-line fluid with no mortality benefit from albumin. 1, 3, 4
• Weak recommendation (GRADE low-quality evidence) supports adding albumin when substantial crystalloids are required, based on physiologic rationale (higher MAP, lower net fluid balance) rather than hard outcomes. 1, 3
• Emerging observational data suggest potential harm (increased AKI risk) without short-term survival benefit, requiring cautious interpretation and further validation. 7
• Trial sequential analysis indicates that the required information size has been nearly reached (88% of 4,894 patients) and the cumulative effect entered the futility area, suggesting further large trials are unlikely to demonstrate benefit. 4